|
1
|
Fassnacht M, Kroiss M and Allolio B:
Update in adrenocortical carcinoma. J Clin Endocrinol Metab.
98:4551–4564. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fassnacht M, Johanssen S, Fenske W,
Weismann D, Agha A, Beuschlein F, Führer D, Jurowich C, Quinkler M,
Petersenn S, et al: Improved survival in patients with stage II
adrenocortical carcinoma followed up prospectively by specialized
centers. J Clin Endocrinol Metab. 95:4925–4932. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Drougat L, Omeiri H, Lefèvre L and
Ragazzon B: Novel insights into the genetics and pathophysiology of
adrenocortical tumors. Front Endocrinol. 6:962015. View Article : Google Scholar
|
|
4
|
Soon PS, Gill AJ, Benn DE, Clarkson A,
Robinson BG, McDonald KL and Sidhu SB: Microarray gene expression
and immunohistochemistry analyses of adrenocortical tumors identify
IGF2 and Ki-67 as useful in differentiating carcinomas from
adenomas. Endocr Relat Cancer. 16:573–583. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Guillaud-Bataille M, Ragazzon B, de
Reyniès A, Chevalier C, Francillard I, Barreau O, Steunou V,
Guillemot J, Tissier F, Rizk-Rabin M, et al: IGF2 promotes growth
of adrenocortical carcinoma cells, but its overexpression does not
modify phenotypic and molecular features of adrenocortical
carcinoma. PLoS One. 9:e1037442014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wandoloski M, Bussey KJ and Demeure MJ:
Adrenocortical cancer. Surg Clin North Am. 89:1255–1267. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Assié G, Letouzé E, Fassnacht M, Jouinot
A, Luscap W, Barreau O, Omeiri H, Rodriguez S, Perlemoine K,
René-Corail F, et al: Integrated genomic characterization of
adrenocortical carcinoma. Nat Genet. 46:607–612. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lin SR, Lee YJ and Tsai JH: Mutations of
the p53 gene in human functional adrenal neoplasms. J Clin
Endocrinol Metab. 78:483–491. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hsu CH, Lee SC, Yang YC, Lian ST, Shin SJ
and Lin SR: The p53 codon 249 mutant-derived from human functional
adrenal tumors-can modify the cell shape of normal adrenocortical
transfected cells. Cancer Lett. 170:63–71. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tissier F, Cavard C, Groussin L,
Perlemoine K, Fumey G, Hagneré AM, René-Corail F, Jullian E,
Gicquel C, Bertagna X, et al: Mutations of beta-catenin in
adrenocortical tumors: Activation of the Wnt signaling pathway is a
frequent event in both benign and malignant adrenocortical tumors.
Cancer Res. 65:7622–7627. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Clough E and Barrett T: The gene
expression Omnibus database. Methods Mol Biol. 1418:93–110. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee JS: Exploring cancer genomic data from
the cancer genome atlas project. BMB Rep. 49:607–611. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gautier L, Cope L, Bolstad BM and Irizarry
RA: Affy-analysis of Affymetrix GeneChip data at the probe level.
Bioinformatics. 20:307–315. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expression
analyses for RNA-sequencing and microarray studies. Nucleic Acids
Res. 43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Harris MA, Clark J, Ireland A, Lomax J,
Ashburner M, Foulger R, Eilbeck K, Lewis S, Marshall B, Mungall C,
et al: The Gene Ontology (GO) database and informatics resource.
Nucleic Acids Res. 32:D258–D261. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Weiss LM, Medeiros LJ and Vickery AL:
Pathologic features of prognostic significance in adrenocortical
carcinoma. Am J Surg Pathol. 13:202–206. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Aubert S, Wacrenier A, Leroy X, Devos P,
Carnaille B, Proye C, Wemeau JL, Lecomte-Houcke M and Leteurtre E:
Weiss system revisited: A clinicopathologic and immunohistochemical
study of 49 adrenocortical tumors. Am J Surg Pathol. 26:1612–1619.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu T, Brown TC, Juhlin CC, Andreasson A,
Wang N, Bäckdahl M, Healy JM, Prasad ML, Korah R, Carling T, et al:
The activating TERT promoter mutation C228T is recurrent in
subsets of adrenal tumors. Endocr Relat Cancer. 21:427–434. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Strausfeld U and Richter A: Simultaneous
purification of DNA topoisomerase I and II from eukaryotic cells.
Prep Biochem. 19:37–48. 1989.PubMed/NCBI
|
|
23
|
Qian X, Song X, He Y, Yang Z, Sun T, Wang
J, Zhu G, Xing W and You C: CCNB2 overexpression is a poor
prognostic biomarker in Chinese NSCLC patients. Biomed
Pharmacother. 74:222–227. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Qu Y, Li J, Cai Q and Liu B: Hec1/Ndc80 is
overexpressed in human gastric cancer and regulates cell growth. J
Gastroenterol. 49:408–418. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ploeg M, Aben KK and Kiemeney LA: The
present and future burden of urinary bladder cancer in the world.
World J Urol. 27:289–293. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu KZ, Wang GN, Fitzgerald J, Quachthithu
H, Rainey MD, Cattaneo A, Bachi A and Santocanale C: DDK dependent
regulation of TOP2A at centromeres revealed by a chemical genetics
approach. Nucleic Acids Res. 44:8786–8798. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Terashima M, Ichikawa W, Ochiai A, Kitada
K, Kurahashi I, Sakuramoto S, Katai H, Sano T, Imamura H and Sasako
M; ACTS-GC Group, : TOP2A, GGH, and PECAM1 are
associated with hematogenous, lymph node, and peritoneal recurrence
in stage II/III gastric cancer patients enrolled in the ACTS-GC
study. Oncotarget. 8:57574–57582. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
de Resende MF, Vieira S, Chinen LT,
Chiappelli F, da Fonseca FP, Guimarães GC, Soares FA, Neves I,
Pagotty S, Pellionisz PA, et al: Prognostication of prostate cancer
based on TOP2A protein and gene assessment: TOP2A in prostate
cancer. J Transl Med. 11:362013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kirk JS, Schaarschuch K, Dalimov Z,
Lasorsa E, Ku S, Ramakrishnan S, Hu Q, Azabdaftari G, Wang J, Pili
R, et al: Top2a identifies and provides epigenetic rationale for
novel combination therapeutic strategies for aggressive prostate
cancer. Oncotarget. 6:3136–3146. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Labbé DP, Sweeney CJ, Brown M, Galbo P,
Rosario S, Wadosky KM, Ku SY, Sjöström M, Alshalalfa M, Erho N, et
al: TOP2A and EZH2 provide early detection of an aggressive
prostate cancer subgroup. Clin Cancer Res. 23:7072–7083. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mu XC, Tran TA, Ross JS and Carlson JA:
Topoisomerase II-alpha expression in melanocytic nevi and malignant
melanoma. J Cutan Pathol. 27:242–248. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Holden JA and Townsend JJ: DNA
topoisomerase II-alpha as a proliferation marker in astrocytic
neoplasms of the central nervous system: Correlation with MIB1
expression and patient survival. Mod Pathol. 12:1094–1100.
1999.PubMed/NCBI
|
|
33
|
Costa MJ, Hansen CL, Holden JA and Guinee
D Jr: Topoisomerase II alpha: Prognostic predictor and cell cycle
marker in surface epithelial neoplasms of the ovary and peritoneum.
Int J Gynecol Pathol. 19:248–257. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dingemans AM, Witlox MA, Stallaert RA, van
der Valk P, Postmus PE and Giaccone G: Expression of DNA
topoisomerase IIalpha and topoisomerase IIbeta genes predicts
survival and response to chemotherapy in patients with small cell
lung cancer. Clin Cancer Res. 5:2048–2058. 1999.PubMed/NCBI
|
|
35
|
Depowski PL, Rosenthal SI, Brien TP,
Stylos S, Johnson RL and Ross JS: Topoisomerase IIalpha expression
in breast cancer: Correlation with outcome variables. Mod Pathol.
13:542–547. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Park SH, Yu GR, Kim WH, Moon WS, Kim JH
and Kim DG: NF-Y-dependent cyclin B2 expression in colorectal
adenocarcinoma. Clin Cancer Res. 13:858–867. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shubbar E, Kovács A, Hajizadeh S, Parris
TZ, Nemes S, Gunnarsdóttir K, Einbeigi Z, Karlsson P and Helou K:
Elevated cyclin B2 expression in invasive breast carcinoma is
associated with unfavorable clinical outcome. BMC Cancer. 13:12013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lei CY, Wang W, Zhu YT, Fang WY and Tan
WL: The decrease of cyclin B2 expression inhibits invasion and
metastasis of bladder cancer. Urol Oncol. 34:237.e1–10. 2016.
View Article : Google Scholar
|
|
39
|
Zhou L, Du Y, Kong L, Zhang X and Chen Q:
Identification of molecular target genes and key pathways in
hepatocellular carcinoma by bioinformatics analysis. Onco Targets
Ther. 11:1861–1869. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yoo TY, Choi JM, Conway W, Yu CH, Pappu RV
and Needleman DJ: Measuring NDC80 binding reveals the molecular
basis of tension-dependent kinetochore-microtubule attachments.
Elife. 7:e363922018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wu G, Qiu XL, Zhou L, Zhu J, Chamberlin R,
Lau J, Chen PL and Lee WH: Small molecule targeting the Hec1/Nek2
mitotic pathway suppresses tumor cell growth in culture and in
animal. Cancer Res. 68:8393–8399. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bièche I, Vacher S, Lallemand F,
Tozlu-Kara S, Bennani H, Beuzelin M, Driouch K, Rouleau E,
Lerebours F, Ripoche H, et al: Expression analysis of mitotic
spindle checkpoint genes in breast carcinoma: Role of
NDC80/HEC1 in early breast tumorigenicity, and a two-gene
signature for aneuploidy. Mol Cancer. 10:232011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Huang LY, Chang CC, Lee YS, Chang JM,
Huang JJ, Chuang SH, Kao KJ, Lau GM, Tsai PY, Liu CW, et al:
Activity of a novel Hec1-targeted anticancer compound against
breast cancer cell lines in vitro and in vivo. Mol Cancer Ther.
13:1419–1430. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Diaz-Rodríguez E, Sotillo R, Schvartzman
JM and Benezra R: Hec1 overexpression hyperactivates the mitotic
checkpoint and induces tumor formation in vivo. Proc Natl Acad Sci
USA. 105:16719–16724. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Puisieux A, Galvin K, Troalen F, Bressac
B, Marcais C, Galun E, Ponchel F, Yakicier C, Ji J and Ozturk M:
Retinoblastoma and p53 tumor suppressor genes in human hepatoma
cell lines. FASEB J. 7:1407–1413. 1993. View Article : Google Scholar : PubMed/NCBI
|
